PLCB3

Across TCGA pan-cancer cohorts, PLCB3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLCB3 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PLCB3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PLCB3 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where PLCB3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.813	0.580	.006	33	view →
LUAD	DFS	Median	All	0.535	0.880	.019	4	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →
GBM	DFS	Quartile	All	0.511	0.864	.025	1	view →
LSCC	DFS	Quartile	III,IV	0.546	1.000	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLCB3–HNSC (OS)

Open the HNSC breakdown →